

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Hruby Dennis E</u> (Last) (First) (Middle) <u>C/O SIGA TECHNOLOGIES, INC.</u> <u>31 EAST 62ND STREET</u> (Street) <u>NEW YORK</u> <u>NY</u> <u>10065</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>SIGA TECHNOLOGIES INC [SIGA]</u> 3. Date of Earliest Transaction (Month/Day/Year) <u>09/11/2018</u> 4. If Amendment, Date of Original Filed (Month/Day/Year)	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>VP & Chief Scientific Officer</u> 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
--	---	---

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock, par value \$.0001 per share	09/11/2018		M		18,174 ⁽¹⁾⁽²⁾	A	\$3.53	226,314	D	
Common Stock, par value \$.0001 per share	09/11/2018		F		8,853 ⁽¹⁾⁽²⁾	D	\$7.16	217,461	D	
Common Stock, par value \$.0001 per share	09/11/2018		M		50,000 ⁽⁴⁾	A	\$4.7	267,461	D	
Common Stock, par value \$.0001 per share	09/11/2018		F		32,821 ⁽⁴⁾	D	\$7.16	234,640	D	
Common Stock, par value \$.0001 per share	09/11/2018		M		25,000 ⁽⁶⁾	A	\$0	259,640	D	
Common Stock, par value \$.0001 per share	09/11/2018		F		12,175 ⁽⁶⁾	D	\$7.16	247,465	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock-Settled Stock Appreciation Rights	\$3.53	09/11/2018		M			37,500	⁽³⁾	02/02/2022	Common Stock, par value \$.0001 per share	37,500	\$0	0	D	
Stock Option (Right to buy)	\$4.7	09/11/2018		M			50,000	⁽⁵⁾	03/05/2019	Common Stock, par value \$.0001 per share	50,000	\$0	0	D	
Restricted Stock Units	⁽⁷⁾	09/11/2018		M			25,000	⁽⁷⁾	⁽⁷⁾	Common Stock, par value \$.0001 per share	25,000	\$0	0	D	

Explanation of Responses:

1. This Form 4 reports the exercise of 37,500 stock-settled appreciation rights ("SSARs") for shares of common stock of SIGA Technologies, Inc. (the "Issuer") granted on February 12, 2012 and the related surrender to the Issuer of 8,853 shares of common stock of the Issuer by the Reporting Person in order to satisfy certain tax withholding obligations of the Issuer associated with the exercise of SSARs and the consequent issuance of common stock of the Issuer. No shares of common stock of the Issuer were sold by the Reporting Person in a market transaction.
2. Each SSAR consists of the right to receive an amount, in common stock, equal to the excess of the fair market value of a share of common stock of the Issuer (subject to a cap on the fair market value at \$7.00 per share) on the date of exercise over the exercise price of such SSAR. The number of shares of common stock issued was determined by dividing the total of all exercised SSARs by the fair market value of a share of common stock of the Issuer on the date of exercise.
3. The SSARs vested in equal yearly installments over a period of three (3) years, with the first 1/3 of such SSARs vesting on February 2, 2013, the second 1/3 of such SSARs vesting on February 2, 2014, and the remaining 1/3 of such SSARs vesting on February 2, 2015.
4. This Form 4 reports the exercise of options for 50,000 shares of common stock of the Issuer granted on March 5, 2009 and the related surrender to the Issuer of 32,821 shares of common stock of the Issuer by the Reporting Person in order to effect the option exercise. No shares of common stock of the Issuer were sold by the Reporting Person in a market transaction.
5. The options vested in equal yearly installments over a period of three (3) years, with the first 1/3 of such options vesting on March 5, 2010, the second 1/3 of such options vesting on March 5, 2011, and the remaining 1/3 of such options vesting on March 5, 2012.
6. This Form 4 reports the vesting of 25,000 restricted stock units ("RSUs") granted on June 8, 2017 and the consequent issuance of common stock of the Issuer, and the related surrender to the Issuer of 12,175 shares of common stock of the Issuer by the Reporting Person in order to satisfy certain tax withholding obligations of the Issuer associated with the vesting of RSUs and the consequent issuance of common stock of the Issuer. No shares of common stock of the Issuer were sold by the Reporting Person in a market transaction. Each RSU converts into one share of common stock of the Issuer on a one for one basis.
7. The RSUs vested upon the U.S. Food & Drug Administration's final approval of TPOXX for the treatment of orthopoxvirus infections.

/s/ Dennis E. Hruby

09/13/2018

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.